Sonya Del Tredici and John Keenan

Addiction Medicine Journal Club

Sonya Del Tredici and John Keenan

  • 31-40 Round-Up

31-40 Round-Up

Monday 6th May 2024

Summaries of key studies from Episodes 31-40, covering naloxone training, trazodone for sleep, opioid agonist risks, and more.
63 minutes
Informative
Educational
Supportive
Encouraging
Non-judgmental

About this podcast

Addiction Medicine Journal Club
Author:
Sonya Del Tredici and John Keenan
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Navigating Intimate Relationships
Family Recovery from Addiction
Nutritional Pathways to Recovery
Episodes:
69 (View all)
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Addiction Medicine Journal Club: Episodes 31-40 Round-Up

Episode Overview

  • Take-home naloxone training does not increase drug use frequency.
  • Trazodone is effective for sleep disturbances in opioid-dependent patients.
  • No significant overdose risk when prescribing opioid agonists with other medications.
  • Higher buprenorphine doses may be needed in the fentanyl era.
  • Removing Medicaid prior authorization can increase buprenorphine treatment uptake.
Giving out Naloxone is not going to make people use more drugs
In this episode of Addiction Medicine Journal Club, Dr. Sonia del Tredici and Dr. John Keenan bring you quick summaries of Episodes 31-40, covering a wide range of topics related to addiction medicine. From the impact of take-home naloxone training on injection drug use frequency to the effectiveness of trazodone for sleep disturbances in opioid-dependent patients, this episode is packed with valuable insights for healthcare professionals.
You'll also hear about the risks associated with prescribing opioid agonists alongside other medications, the best buprenorphine doses in the era of fentanyl, and the effects of removing Medicaid prior authorization requirements on buprenorphine treatment. The episode doesn't stop there; it dives into emotional dysregulation factors linked to problematic smartphone use, and even compares the cost-effectiveness of monthly extended-release buprenorphine versus daily standard care medication.
With detailed discussions on each study, this episode offers a comprehensive overview of the latest research in addiction medicine. Whether you're a busy doctor, PA, or NP, this episode provides a wealth of information to help you stay up-to-date with current practices. Don't miss out on these key findings that could shape your approach to treating addiction.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.